Literature DB >> 20382575

Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry.

R Honeywell1, K Yarzadah, E Giovannetti, N Losekoot, E F Smit, M Walraven, J S W Lind, C Tibaldi, H M Verheul, G J Peters.   

Abstract

A fast, sensitive, universal and accurate method for the determination of four different tyrosine kinase inhibitors from biological material was developed using LC-MS/MS techniques. Utilizing a simple protein precipitation with acetonitrile a 20 microl sample volume of biological matrixes can be extracted at 4 degrees C with minimal effort. After centrifugation the sample extract is introduced directly onto the LC-MS/MS system without further clean-up and assayed across a linear range of 1-4000 ng/ml. Chromatography was performed using a Dionex Ultimate 3000 with a Phenomenex prodigy ODS3 (2.0 mm x 100 mm, 3 microm) column and eluted at 200 microl/min with a tertiary mobile phase consisting of 20mM ammonium acetate:acetonitrile:methanol (2.5:6.7:8.3%). Injection volume varied from 0.1 microl to 1 microl depending on the concentration of the drug observed. Samples were observed to be stable for a maximum of 48 h after extraction when kept at 4 degrees C. Detection was performed using a turbo-spray ionization source and mass spectrometric positive multi-reaction-monitoring-mode (+MRM) for Gefitinib (447.1 m/z; 127.9 m/z), Erlotinib (393.9 m/z; 278.2 m/z), Sunitinib (399.1 m/z; 283.1 m/z) and Sorafenib (465.0 m/z; 251.9 m/z) at an ion voltage of +3500 V. The accuracy, precision and limit-of-quantification (LOQ) from cell culture medium were as follows: Gefitinib: 100.2+/-3.8%, 11.2 nM; Erlotinib: 101.6+/-3.7%, 12.7 nM; Sunitinib: 100.8+/-4.3%, 12.6 nM; Sorafenib: 93.9+/-3.0%, 10.8 nM, respectively. This was reproducible for plasma, whole blood, and serum. The method was observed to be linear between the LOQ and 4000 ng/ml for each analyte. Effectiveness of the method is illustrated with the analysis of samples from a cellular accumulation investigation and from determination of steady state concentrations in clinically treated patients. 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20382575     DOI: 10.1016/j.jchromb.2010.03.010

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  13 in total

1.  Sunitinib LC-MS/MS Assay in Mouse Plasma and Brain Tissue: Application in CNS Distribution Studies.

Authors:  Rajneet K Oberoi; Rajendar K Mittapalli; James Fisher; William F Elmquist
Journal:  Chromatographia       Date:  2013-12-01       Impact factor: 2.044

2.  Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance.

Authors:  Kristy J Gotink; Henk J Broxterman; Mariette Labots; Richard R de Haas; Henk Dekker; Richard J Honeywell; Michelle A Rudek; Laurens V Beerepoot; René J Musters; Gerrit Jansen; Arjan W Griffioen; Yehuda G Assaraf; Roberto Pili; Godefridus J Peters; Henk M W Verheul
Journal:  Clin Cancer Res       Date:  2011-10-06       Impact factor: 12.531

3.  Therapeutic drug monitoring and tyrosine kinase inhibitors.

Authors:  Pauline Herviou; Emilie Thivat; Damien Richard; Lucie Roche; Joyce Dohou; Mélanie Pouget; Alain Eschalier; Xavier Durando; Nicolas Authier
Journal:  Oncol Lett       Date:  2016-06-24       Impact factor: 2.967

4.  Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma.

Authors:  Elizabeth A Kuczynski; Christina R Lee; Shan Man; Eric Chen; Robert S Kerbel
Journal:  Cancer Res       Date:  2015-04-23       Impact factor: 12.701

5.  Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature.

Authors:  Kristy J Gotink; Henk J Broxterman; Richard J Honeywell; Henk Dekker; Richard R de Haas; Kiersten M Miles; Remi Adelaiye; Arjan W Griffioen; Godefridus J Peters; Roberto Pili; Henk M W Verheul
Journal:  Oncoscience       Date:  2014-12-15

6.  Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib.

Authors:  Kristy J Gotink; Maria Rovithi; Richard R de Haas; Richard J Honeywell; Henk Dekker; Dennis Poel; Kaamar Azijli; Godefridus J Peters; Henk J Broxterman; Henk M W Verheul
Journal:  Cell Oncol (Dordr)       Date:  2015-02-11       Impact factor: 6.730

7.  Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction.

Authors:  Esther A Kleibeuker; Matthijs A Ten Hooven; Kitty C Castricum; Richard Honeywell; Arjan W Griffioen; Henk M Verheul; Ben J Slotman; Victor L Thijssen
Journal:  Cancer Med       Date:  2015-03-31       Impact factor: 4.452

8.  Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth.

Authors:  Maria Rovithi; Richard R de Haas; Richard J Honeywell; Dennis Poel; Godefridus J Peters; Arjan W Griffioen; Henk M W Verheul
Journal:  J Exp Clin Cancer Res       Date:  2016-09-07

9.  Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors.

Authors:  Maria Rovithi; Sophie L Gerritse; Richard J Honeywell; Albert J Ten Tije; Rita Ruijter; Godefridus J Peters; Jens Voortman; Mariette Labots; Henk M W Verheul
Journal:  J Clin Oncol       Date:  2018-12-26       Impact factor: 44.544

10.  Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome.

Authors:  Mariette Labots; Thang V Pham; Richard J Honeywell; Jaco C Knol; Robin Beekhof; Richard de Goeij-de Haas; Henk Dekker; Maarten Neerincx; Sander R Piersma; Johannes C van der Mijn; Donald L van der Peet; Martijn R Meijerink; Godefridus J Peters; Nicole C T van Grieken; Connie R Jiménez; Henk M W Verheul
Journal:  Cancers (Basel)       Date:  2020-02-01       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.